skip to content
Primary navigation

Rapaflo

Drug - Rapaflo (silodosin)

August 2010

Therapeutic area - benign prostatic hyperplasia (BPH)

FDA approved indication

Rapaflo, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Available as capsules: 8 mg and 4 mg

Criteria

Patient has been tried on each of the following without success: 

  • doxazosin mesylate  (Cardura) 
  • tamsulosin   (Flomax) 
  • terazosin  (Hytrin)  

Rationale

Rapaflo is available only as a branded medication and is associated with a list price of about $4.18/tablet. Conversely, other alpha blockers, doxazosin mesylate, tamsulosin hcl, terazosin hcl are all available as generic formulations and are available from $0.10 to $0.50, and are expected to offer the same efficacy profile. 

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top